AbbVie Backpedals On Landmark Inversion After Rule Tweaks
U.S. drugmaker AbbVie Inc. said late Tuesday that its historic $54 billion tax-inversion deal could be in trouble after the Obama administration leveled restrictions meant to curb benefits tied to such...To view the full article, register now.
Already a subscriber? Click here to view full article